Kenvue Inc. (NYSE:KVUE) Shares Acquired by NEOS Investment Management LLC

NEOS Investment Management LLC boosted its position in Kenvue Inc. (NYSE:KVUE) by 31.5% during the 4th quarter, Holdings Channel reports. The fund owned 103,849 shares of the company’s stock after acquiring an additional 24,888 shares during the quarter. NEOS Investment Management LLC’s holdings in Kenvue were worth $2,217,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the company. Grove Bank & Trust lifted its holdings in Kenvue by 438.4% during the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after buying an additional 947 shares during the last quarter. Geneos Wealth Management Inc. acquired a new position in Kenvue in the fourth quarter valued at approximately $29,000. SRS Capital Advisors Inc. increased its stake in Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock valued at $30,000 after purchasing an additional 571 shares during the last quarter. Fortitude Family Office LLC raised its holdings in Kenvue by 106.6% during the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after purchasing an additional 777 shares in the last quarter. Finally, Versant Capital Management Inc raised its holdings in Kenvue by 300.8% during the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock worth $41,000 after purchasing an additional 1,441 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on KVUE. Barclays increased their target price on shares of Kenvue from $21.00 to $23.00 and gave the company an “equal weight” rating in a research report on Thursday. Citigroup dropped their price objective on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday, January 15th. Evercore ISI started coverage on Kenvue in a report on Monday, March 24th. They issued an “in-line” rating and a $25.00 target price for the company. Royal Bank of Canada restated a “sector perform” rating and set a $24.00 price target on shares of Kenvue in a research note on Monday, February 3rd. Finally, Canaccord Genuity Group boosted their price objective on Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a research note on Wednesday, March 5th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $24.00.

Kenvue Stock Performance

NYSE:KVUE opened at $23.74 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The firm has a market cap of $45.36 billion, a price-to-earnings ratio of 44.78, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. The firm’s fifty day moving average price is $22.32 and its 200 day moving average price is $22.46. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, sell-side analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were paid a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.45%. The ex-dividend date was Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is 154.72%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.